Evidence map›Paper›PMID 39172530›Full record

ArticleJCI insight2024

MerTK-dependent efferocytosis by monocytic-MDSCs mediates resolution of ischemia/reperfusion injury after lung transplant.

Victoria Leroy, Denny J Manual Kollareth, Zhenxiao Tu, Jeff Arni C Valisno, Makena Woolet-Stockton, Biplab Saha, Amir M Emtiazjoo, Mindaugas Rackauskas, Lyle L Moldawer, Philip A Efron and 4 more

Abstract read
In one paragraph

Article in JCI insight, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. LDLRJournal of clinical and translational hepatology · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Resolvin D2/GPR18 signaling enhances monocytic myeloid-derived suppressor cell function to mitigate abdominal aortic aneurysm formation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Victoria LeroyDepartment of Surgery.
Denny J Manual KollarethDepartment of Surgery.
Zhenxiao TuDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Jeff Arni C ValisnoDepartment of Surgery.
Makena Woolet-StocktonDepartment of Surgery.
Biplab SahaDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Amir M EmtiazjooDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Mindaugas RackauskasDepartment of Surgery.
Lyle L MoldawerDepartment of Surgery.
Philip A EfronDepartment of Surgery.
Guoshuai CaiDepartment of Surgery.
Carl AtkinsonDepartment of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Gilbert R UpchurchDepartment of Surgery.
Ashish K SharmaDepartment of Surgery.

Funding

Renewal: Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis PathobiologyRM1GM139690 · NIGMS · UNIVERSITY OF FLORIDA · PI Philip A Efron, Michael Paul Kladde · 2021 to 2026
$10.3M
R35 Equipment SupplementR35GM140806 · NIGMS · UNIVERSITY OF FLORIDA · PI EFRON, PHILIP A · 2021 to 2025
$2.2M
Complement driven innate and adaptive autoreactivity in lung transplantationR01HL140470 · NHLBI · UNIVERSITY OF FLORIDA · PI ATKINSON, CARL · 2018 to 2021
$2.0M
Monocytic-MDSCs as resolution mediators of post-transplant lung ischemia-reperfusion injuryF31HL168827 · NHLBI · UNIVERSITY OF FLORIDA · PI LEROY, VICTORIA · 2023 to 2023
$39k
NHLBI NIH HHS F31 HL168827NHLBI NIH HHS R01 HL140470NIGMS NIH HHS R35 GM140806NIGMS NIH HHS RM1 GM139690
6 · The paper itself

Abstract

Lung transplantation (LTx) outcomes are impeded by ischemia/reperfusion injury (IRI) and subsequent chronic lung allograft dysfunction (CLAD). We examined the undefined role of receptor Mer tyrosine kinase (MerTK) on monocytic myeloid-derived suppressor cells (M-MDSCs) in efferocytosis to facilitate resolution of lung IRI. Single-cell RNA sequencing of lung tissue and bronchoalveolar lavage (BAL) from patients after LTx were analyzed. Murine lung hilar ligation and allogeneic orthotopic LTx models of IRI were used with BALB/c (WT), Cebpb-/- (MDSC-deficient), Mertk-/-, or MerTK-cleavage-resistant mice. A significant downregulation in MerTK-related efferocytosis genes in M-MDSC populations of patients with CLAD was observed compared with healthy individuals. In the murine IRI model, a significant increase in M-MDSCs, MerTK expression, and efferocytosis and attenuation of lung dysfunction was observed in WT mice during injury resolution that was absent in Cebpb-/- and Mertk-/- mice. Adoptive transfer of M-MDSCs in Cebpb-/- mice significantly attenuated lung dysfunction and inflammation. Additionally, in a murine orthotopic LTx model, increases in M-MDSCs were associated with resolution of lung IRI in the transplant recipients. In vitro studies demonstrated the ability of M-MDSCs to efferocytose apoptotic neutrophils in a MerTK-dependent manner. Our results suggest that MerTK-dependent efferocytosis by M-MDSCs can substantially contribute to the resolution of post-LTx IRI.

Indexed as

c-Mer Tyrosine KinaseLung TransplantationMyeloid-Derived Suppressor CellsReperfusion InjuryAnimalsCCAAT-Enhancer-Binding Protein-betaDisease Models, AnimalEfferocytosisFemaleHumansLungMaleMiceMice, Inbred BALB CMice, KnockoutMonocytesCCAAT-Enhancer-Binding Protein-betac-Mer Tyrosine KinaseMERTK protein, humanMertk protein, mouseImmunologyInnate immunityMonocytesSurgeryTransplantation

Identifiers

PMID39172530
PMCPMC11466183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.